hMSCs & Their Exosome/EV Secretomes — Time To Think Globally With Locally Acting Anti-Fibrotic Therapies

In the developed world, a surprising 45% of all mortality is driven by severe fibroproliferative disease processes of the inner organs and circulatory system. At this time, approved medications to directly treat fibrosis only relieve symptoms, and these drugs usually don’t directly antagonize the molecular drivers of this disease class. Take a look at important information and data from PubMed publications regarding cancer and fibrosis research and as well as learning about MSCs & their EVs/Exosomes.